Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02255500 · ClinicalTrials.gov registry record · Phase 4
EXPAREL Infiltration in Subjects Undergoing Femoral Nerve Block With Bupivacaine HCl for Total Knee Arthroplasty
A Phase 4 study, sponsored by Pacira Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 23
- Enrollment target
NCT02255500 is a Phase 4 study that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 23 participants.
The verdict
NCT02255500, a Phase 4 study, has completed, sponsored by Pacira Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and pharmacokinetics of EXPAREL in subjects who undergo femoral nerve block with bupivacaine HCl for unilateral total knee arthroplasty (TKA).
Interventions
- DRUG EXPAREL Infiltration
- DRUG Bupivacaine FNB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02255500
The ClinicalTrials.gov registry entry for NCT02255500 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EXPAREL Infiltration is the first listed.
NCT02255500 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02255500 about?
NCT02255500 is a clinical study titled "EXPAREL Infiltration in Subjects Undergoing Femoral Nerve Block With Bupivacaine HCl for Total Knee Arthroplasty". The purpose of this study is to evaluate the safety and pharmacokinetics of EXPAREL in subjects who undergo femoral nerve block with bupivacaine HCl for unilateral total knee arthroplasty (TKA).
What is the current status of trial NCT02255500?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2014-09. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02255500?
The interventions under investigation include: EXPAREL Infiltration (DRUG), Bupivacaine FNB (DRUG).
Who is sponsoring clinical trial NCT02255500?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.